Calmark participates in a Business Delegation visit to Rwanda and meets with VIA Global Health

Report this content

Calmark Sweden AB (publ) announced today that representatives from the company will participate in a delegation trip to Rwanda on November 8-9 organized by Swecare, in collaboration with the Ministry of Foreign Affairs, the Ministry of Health and Social Affairs, the Embassy of Sweden in Rwanda and the Embassy of Rwanda in Sweden. Representatives from Calmark's distributor in Africa, VIA Global Health, will also participate in parts of the two-day program.

Swecare is a foundation that was established in 1978 and whose mission is to contribute to increased exports of Swedish products, services and knowledge in the life science area. International delegation trips are part of Swecare's core business, and this will be the fourth trip to Rwanda in eight years.

The main purpose of the trip is to give Swedish companies access to key decision and policymakers at public regulatory entities and potential clients in the public and private healthcare sector. Head of delegation is Agneta Karlsson, Chairman of the Swecare board and Director General at The Dental and Pharmaceutical Benefits Agency (TLV). Participating from Calmark will be Magdalena Tharaldsen, Director International Business Development and Camilla Arneving, Marketing Director.

The official program is under development but is expected to include visits to:

  • Ministry of Health
  • Rwanda Biomedical Centre (RBC)
  • Rwanda Food and Drug Authority FDA
  • Rwanda Development Board
  • Rwanda Medical Supply
  • Study visits to hospitals
  • University of Rwanda

‘We are very much looking forward to being a part of this comprehensive trip that accelerates the launch in Africa,’ says Magdalena Tharaldsen, Director International Business Development for Calmark. ‘During the visit to Kigali, we will also meet with potential local sub-distributors together with key people at VIA Global Health. This in itself means an important step forward in our collaboration.’

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93

Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at  



Documents & Links